FAST-PLV Senolytic Therapy (Oisin biotechnologies/University of Alberta/Entos Pharmaceuticals/Istituto Nazionale Riposo e Cura Anziani)

N/A

Report date: 2025/01/26 18:04:58
NME

Base Information

Drug NameFAST-PLV Senolytic Therapy (Oisin biotechnologies/University of Alberta/Entos Pharmaceuticals/Istituto Nazionale Riposo e Cura Anziani)
Drug Alias NameiCasp9 gene therapy (Oisin biotechnologies/University of Alberta/Entos Pharmaceuticals/Istituto Nazionale Riposo e Cura Anziani)
ClassificationSmall molecules > LipidSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide
Mechanisms of ActionCaspase-9 activators
TargetsCaspase-9
Therapy Area/IndicationsHealthy AgingSarcopenia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesItaly
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesOisin Biotechnologies Inc
China Registration ClassN/A

Develop Information

Active CompaniesIstituto Nazionale Di Ricovero E Cura Per AnzianiOisin Biotechnologies IncUniversity Of Alberta +[4] 
Inactive CompaniesN/A
Active IndicationsHealthy AgingSarcopenia
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A